National Cancer Institute CARCINOGENESIS Technical Report Series No. 23 1978

BIOASSAY OF PICLORAM FOR POSSIBLE CARCINOGENICITY

CAS No. 1918-02-1

NCI-CG-TR-23

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health **BIOASSAY OF**

PICLORAM

FOR POSSIBLE CARCINOGENICITY

Carcinogen Bioassay and Program Resources Branch Carcinogenesis Program Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health Bethesda, Maryland 20014

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health

DHEW Publication No. (NIH) 78-823

BIOASSAY OF PICLORAM FOR POSSIBLE CARCINOGENICITY

Carcinogenesis Program Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health

<u>CONTRIBUTORS</u>: This report presents the results of the bioassay of picloram for possible carcinogenicity, conducted for the Carcinogen Bioassay and Program Resources Branch, Carcinogenesis Program, Division of Cancer Cause and Prevention, National Cancer Institute (NCI), Bethesda, Maryland. The bioassay was conducted by Gulf South Research Institute, New Iberia, Louisiana, initially under direct contract to NCI and currently under a subcontract to Tracor Jitco, Inc., prime contractor for the NCI carcinogenesis bioassay program.

The experimental design was determined by Drs. J. H. Weisburger^{1,2} and R. R. Bates^{1,3}; the doses were selected by Drs. T. E. Shellenberger^{4,5}, J. H. Weisburger, and R. R. Bates. Animal treatment and observation were supervised by Drs. T. E. Shellenberger and H. P. Burchfield⁴, with the technical assistance of Ms. D. H. Monceaux⁴ and Mr. D. Broussard⁴. Histopathology was performed by Drs. E. Bernal⁴ and B. Buratto⁴, and the diagnoses included in this report represent the interpretation of these pathologists.

Animal pathology tables and survival tables were complied at EG&G Mason Research Institute⁶. Statistical analyses were performed by Dr. J. R. Joiner⁷, using methods selected for the bioassay program by Dr. J. J. Gart⁸. Chemicals used in this bioassay were analyzed under the direction of Dr. H. P. Burchfield, and the analytical results were reviewed by Dr. S. S. Olin⁷.

This report was prepared at Tracor Jitco under the direction of Dr. Marshall Steinberg⁷, Director of the Bioassay Program; Drs. J. F. Robens⁷ and R. W. Fogleman⁷, toxicologists; Dr. R. L.

Schueler⁷, patholigist; Ms. L. A. Waitz⁷ and Ms. Y. E. Presley⁷, technical writers; and Dr. E. W. Gunberg⁷, technical editor, assisted by Ms. P. J. Graboske⁷.

The statistical analysis was reviewed by a member or members of the Mathematical Statistics and Applied Mathematics Section of NCI (Dr. John J. Gart, Mr. Jun-mo Nam, Dr. Hugh M. Pettigrew, and Dr. Robert E. Tarone served as reviewers on an alternating basis).

The following other scientists at the National Cancer Institute were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings:

> Dr. Kenneth C. Chu Dr. Cipriano Cueto, Jr. Dr. J. Fielding Douglas Dr. Dawn G. Goodman Dr. Richard A. Griesemer Mr. Harry A. Milman Dr. Thomas W. Orme Dr. Robert A. Squire⁹ Dr. Jerrold M. Ward

¹Carcinogenesis Program, Divison of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

²Now with the Naylor Dana Institute for Disease Prevention, American Health Foundation, Hammond House Road, Valhalla, New York.

³Now with the Office of the Commissioner, Food and Drug Administration, Rockville, Maryland.

⁴Gulf South Research Institute, Atchafalaya Basin Laboratories, P. O. Box 1177, New Iberia, Louisiana.

⁵Now with the National Center for Toxicological Research, Jefferson, Arkansas. ⁶EG&G Mason Research Institute, 1530 East Jefferson Street, Rockville, Maryland.

⁷Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville, Maryland.

⁸Mathematical Statistics and Applied Mathematics Section, Biometry Branch, Field Studies and Statistics, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

⁹Now with the Division of Comparative Medicine, Johns Hopkins University, School of Medicine, Traylor Building, Baltimore, Maryland.

SUMMARY

A bioassay of technical-grade picloram for possible carcinogenicity was conducted by administering the test chemical in feed to Osborne-Mendel rats and B6C3F1 mice.

Groups of 50 rats and 50 mice of each sex were administered picloram in the diet at one of the following doses for 80 weeks. Time-weighted average doses for the rats were 7,437 or 14,875ppm; those for the mice were 2,531 or 5,062 ppm. The rats were then observed for 33 weeks, the mice for 10 weeks. Matched controls consisted of groups of 10 untreated rats or 10 untreated mice of each sex; pooled controls, used for statistical evaluation, consisted of the matched-control groups combined with 30 untreated male and 30 untreated female rats or mice from similar bioassays of three other test chemicals. All surviving rats were killed at 113 weeks; all surviving mice were killed at Survival was adequate for meaningful statistical 90 weeks. analyses of the incidences of tumors in rats and mice of both sexes.

Mean body weights of the high-dose rats were lower than those of the matched controls during the first part of the study; however, beginning at approximately 80 weeks, mean weights of controls were lower than those of treated animals. Body weights of the mice were unaffected by the picloram.

In rats, a relatively high incidence of follicular hyperplasia, C-cell hyperplasia, and C-cell adenoma of the thyroid occurred in both sexes. However, the statistical tests for adenoma did not show sufficent evidence for association of the tumor with picloram administration.

An increased incidence of hepatic neoplastic nodules was observed in treated male and female rats as compared with untreated animals. This lesion is considered to be a benign tumor. In male rats the lesion appeared only in three animals of the low-dose treatment group and was not significant when compared with the controls; however, the test for positive dose-related trend in females was significant (pooled controls 0/39, low-dose 5/50, high-dose 7/49, P = 0.016) and the incidence in the high-dose group was significant (P = 0.014) when compared with that in the pooled-control group.

There was also one hepatocellular carcinoma in a low-dose male rat and one in a high-dose female rat. In both males and females, there was a possibly treatment-related lesion of the liver diagnosed as foci of cellular alteration. The incidences of this latter lesion were, female rats: matched controls 1/10, low-dose 8/50, high-dose 18/49; male rats: matched controls 0/10, low-dose 12/49, high-dose 5/49. Thus, there is evidence that picloram affected the livers of rats of both sexes, but more particularly those of the females.

No tumors were found in male or female mice or male rats at incidences that could be significantly associated with treatment, and it is concluded that picloram was not carcinogenic for B6C3F1 mice or male Osborne-Mendel rats.

In female rats, however, the incidence of neoplastic nodules of the liver, benign tumors, was associated with treatment with picloram. It is concluded that under the conditions of the bioassay, the findings are suggestive of the ability of the compound to induce benign tumors in the livers of female Osborne-Mendel rats.

viii

TABLE OF CONTENTS

I.	Intro	duction	1		
II.	Mater	ials and Methods	3		
	A. B. C. D. E. F. G. H.	Chemical Dietary Preparation. Animals. Animal Maintenance. Subchronic Studies. Designs of Chronic Studies. Clinical and Pathologic Examinations. Data Recording and Statistical Analyses.	3 4 5 6 7 10 11		
111.	Resu	lts - Rats	17		
	A. B. C. D.	Body Weights and Clinical Signs (Rats) Survival (Rats) Pathology (Rats) Statistical Analyses of Results (Rats)	17 19 19 22		
IV.	Resu	lts - Mice	25		
	A. B. C. D.	Body Weights and Clinical Signs (Mice) Survival (Mice) Pathology (Mice) Statistical Analyses of Results (Mice)	25 27 27 29		
v.	Disc	ussion	31		
VI.	Bibliography				
APPENDIXES					

Appendix A	Summary of the Incidence of Neoplasms in Rats Fed Picloram in the Diet	37
Table Al	Summary of the Incidence of Neoplasms in Male Rats Fed Picloram in the Diet	39
Table A2	Summary of the Incidence of Neoplasms in Female Rats Fed Picloram in the Diet	43

Page

Appendix B	Summary of the Incidence of Neoplasms in Mice Fed Picloram in the Diet	47
Table Bl	Summary of the Incidence of Neoplasms in Male Mice Fed Picloram in the Diet	49
Table B2	Summary of the Incidence of Neoplasms in Female Mice Fed Picloram in the Diet	52
A ppendix C	Summary of the Incidence of Nonneoplastic Lesions in Rats Fed Picloram in the Diet	55
Table Cl	Summary of the Incidence of Nonneoplastic Lesions in Male Rats Fed Picloram in the Diet	57
Table C2	Summary of the Incidence of Nonneoplastic Lesions in Female Rats Fed Picloram in the Diet	62
Appendix D	Summary of the Incidence of Nonneoplastic Lesions in Mice Fed Picloram in the Diet	65
Table Dl	Summary of the Incidence of Nonneoplastic Lesions in Male Mice Fed Picloram in the Diet	67
Table D2	Summary of the Incidence of Nonneoplastic Lesions in Female Mice Fed Picloram in the Diet	69
A ppendix E	Analyses of the Incidence of Primary Tumors in Rats Fed Picloram in the Diet	73
Table El	Analyses of the Incidence of Primary Tumors in Male Rats Fed Picloram in the Diet	75
Table E2	Analyses of the Incidence of Primary Tumors in Female Rats Fed Picloram in the Diet	79
A ppendix F	Analyses of the Incidence of Primary Tumors in Mice Fed Picloram in the Diet	83
Table Fl	Analyses of the Incidence of Primary Tumors in Male Mice Fed Picloram in the Diet	85
Table F2	Analyses of the Incidence of Primary Tumors in Female Mice Fed Picloram in the Diet	87

х

Page

Appendix G	Analysis of Formulated Diets for Concentrations of Picloram			
	TABLES			
Table l	Design of Picloram Chronic Feeding Studies in Rats	8		
Table 2	Design of Picloram Chronic Feeding Studies in Mice	9		
	FIGURES			
Figure l	Growth Curves for Rats Fed Picloram in the Diet	18		
Figure 2	Survival Curves for Rats Fed Picloram in the Diet	20		
Figure 3	Growth Curves for Mice Fed Picloram in the Diet	26		
Figure 4	Survival Curves for Mice Fed Picloram in the Diet	28		

I. INTRODUCTION

Picloram (CAS 1918-02-1; COO237), which is the generic name for 4-amino-3,5,6-trichloropicolinic acid, is a systemic herbicide (Neumeyer, 1973; Spencer, 1973) registered by EPA for only nonfood use to control broadleaf weeds and woody plants (EPA Compendium, 1974). The chemical can replace the plant growth hormone indoleacetic acid, and inhibit the synthesis of protein in plants (Bradley, 1974; EPA Compendium, 1974; Neumeyer, 1973). The persistence of picloram in the soil poses environmental problems associated with contamination of the soil and of surface and subsurface water (Edwards, 1976; EPA Compendium, 1974; Hamaker et al., 1963).

Picloram was selected for testing because of its herbicidal use, and because its persistence in soil and water suggested a potential for long-term, low-level human exposure.

II. MATERIALS AND METHODS

A. Chemical

Technical-grade picloram was obtained in three batches of Lot No. 623816 from Dow Chemical Co., Midland, Michigan, for use in the chronic study. The product was at least 90% pure 4-amino-3,5,6trichloropicolinic acid by the manufacturer's assay, and its identity was confirmed by melting point, elemental analyses, and spectral analyses (infrared, ultraviolet, mass, and nuclear magnetic resonance). Thin-layer chromatography revealed several impurities; no attempt was made to identify or quantitate these impurities.

The picloram was stored at 5° C in the original amber glass containers until used.

B. Dietary Preparation

All diets were formulated using finely ground Wayne[®] Lab Blox (Allied Mills, Inc., Chicago, Ill.) to which was added the required amount of picloram for each dietary concentration. A given amount of the test chemical was first hand-mixed with an approximately equal amount of feed. This mixture was then added slowly with mechanical mixing to a larger quantity of feed to give the desired concentration of the chemical. Acetone

(Mallinckrodt Inc., St. Louis, Mo.) and corn oil (Louana[®], Opelousas Refinery Co., Opelousas, La.) were then added to the feed, each in an amount corresponding to 2% of the final weight of feed. The diets were mixed mechanically for not less than 25 minutes to assure homogeneity of the mixture and evaporation of the acetone. Formulated diets were stored at approximately 17°C until used, but no longer than 1 week.

As a quality control test on the accuracy of preparation of the diets, the concentration of picloram was determined in different batches of formulated diets during the chronic study. The results are summarized in Appendix G. At each dietary concentration, the mean of the analytical concentrations for the samples tested was within 2.5% of the theoretical concentration, and the coefficient of variation was never more than 6.7%. Thus, the evidence indicates that the formulated diets were prepared accurately.

C. Animals

Rats and mice of both sexes, obtained through contracts of the Division of Cancer Treatment, National Cancer Institute, were used in these bioassays. The rats were of the Osborne-Mendel strain obtained from Battelle Memorial Institute, Columbus, Ohio, and the mice were B6C3F1 hybrids obtained from Charles River

Breeding Laboratories, Inc., Wilmington, Massachusetts. On arrival at the laboratory, all animals were quarantined for an acclimation period (rats for 10 days, mice for 12 days) and were then assigned to control and treated groups.

D. Animal Maintenance

All animals were housed in temperature- and humidity-controlled rooms. The temperature range was 22-24°C, and the relative humidity was maintained at 40-70%. The air in each room was changed 10-12 times per hour. Fluorescent lighting provided illumination 10 hours per day. Food and water were presented <u>ad</u> <u>libitum</u>.

The rats were housed individually in hanging galvanized steel mesh cages, and the mice were housed in plastic cages with filter bonnets, five per cage for females, and two or three per cage for males. Initially, rats were transferred once per week to clean cages; later in the study, cages were changed every 2 weeks. Mice were transferred once per week to clean cages with filter bonnets; bedding used for the mice was Absorb-Dri[®] (Lab Products, Inc., Garfield, N.J.). For rats, absorbent sheets under the cages were changed three times per week. Feeder jars and water bottles were changed and sterilized three times per week.

Cages for control and treated mice were placed on separate racks

in the same room. Animal racks for both species were rotated laterally once per week; at the same time, each cage was changed to a different position in the row within the same column. Rats receiving picloram, along with their matched controls, were housed in a room by themselves. Mice receiving picloram were maintained in a room housing mice administered chlorothalonil (CAS 1897-45-6), chloramben (CAS 133-90-4), or endrin (CAS 72-20-8), together with their respective matched controls.

E. <u>Subchronic Studies</u>

Subchronic feeding studies were conducted to estimate the maximum tolerated doses of picloram, on the basis of which low and high concentrations (hereinafter referred to as "low doses" and "high doses") were determined for administration in the bioassay. In these subchronic studies, picloram was added to the animal feed in twofold increasing concentrations, ranging from 1,250 to 20,000 ppm for rats and 1,250 to 30,000 ppm for mice. The treated and matched-control groups each consisted of five male and five female animals. Picloram was provided in feed to the treated groups for 6 weeks, followed by a 2-week period of observation.

For the first 3 weeks of the study, the weights of the male rats receiving 20,000 ppm picloram were slightly lower than those of

the matched controls. However, the mean body weights of the female rats receiving 10,000 or 20,000 ppm were similar to those of the matched controls, except during week 1. No deaths occurred in either sex at doses of 10,000 or 20,000 ppm. The low and high doses for both male and female rats were set at 10,000 and 20,000 ppm for the chronic studies.

Weight gains of male and female mice receiving 5,000 and 10,000 ppm picloram were comparable to those of the matched controls. No deaths occurred in either sex at doses of 5,000 or 10,000 ppm. Of the animals receiving 20,000 ppm, 4/5 males and 3/5 females died. The low and high doses for both male and female mice for the chronic studies were set at 5,000 and 10,000 ppm.

F. Designs of Chronic Studies

The designs of the chronic studies are shown in tables 1 and 2.

Since the numbers of animals in the matched-control groups were small, pooled-control groups also were used for statistical comparisons. Matched controls from the current studies on picloram were combined with matched controls from studies on phosphamidon (CAS 13171-21-6), tetrachlorvinphos (CAS 961-11-5), and chloramben (CAS 133-90-4). The pooled controls for statistical tests using rats consisted of 40 males and 40 females; using mice, 40 males and 40 females. The studies on chemicals other

Sex and Treatment <u>Group</u>	Initial No. of <u>Animals</u> ^a	Picloram in Diet <u>(ppm)</u>	<u>Time on Study</u> Treated Untreated (weeks) ^b (weeks) ^C	Time-Weighted Average Dose ^d (ppm)
Male				
Matched-Control	10	0	113	
Low-Dose	50	10,000 5,000 0	39 41 33	7,437
High-Dose	50	20,000 10,000 0	39 41 33	14,875
Female				
Matched-Control	10	0	113	
Low-Dose	50	10,000 5,000 0	39 41 33	7,437
High-Dose	50	20,000 10,000 0	39 41 33	14,875

Table 1. Design of Picloram Chronic Feeding Studies in Rats

^aAll animals were 35 days of age when placed on study.

^bDoses of picloram were lowered at 39 weeks on study, since it was believed that excessive mortality would occur before termination of the study, based on the pattern of mortality, weight changes, and the general condition of rats used in similar studies on other chemicals at Gulf South Research Institute.

^CWhen test diets were discontinued, treated and control rats were fed control diets without corn oil for 4 weeks, then control diets (2% corn oil added) for an additional 29 weeks.

 $d_{\text{Time-weighted average dose}} = \frac{\sum (\text{dose in ppm x no. of weeks at that dose})}{\sum (\text{no. of weeks receiving each dose})}$

Sex and Treatment <u>Group</u>	Initial No. of <u>Animals</u> ^a	Picloram in Diet <u>(ppm)</u>	Treated	n Study Untreated (weeks) ^C	Time-Weighted Average Dose ^C (ppm)
Male					
Matched-Control	10	0		90	
Low-Dose	50	5,000 2,500 0	1 79	10	2,531
High-Dose	50	10,000 5,000 0	1 79	10	5,062
Female					
Matched-Control	10	0		90	
Low-Dose	50	5,000 2,500 0	1 79	10	2,531
High-Dose	50	10,000 5,000 0	1 79	10	5,062

Table 2. Design of Picloram Chronic Feeding Studies in Mice

^aAll animals were 35 days of age when placed on study.

^bDoses of picloram were lowered at 1 week on study, since it was believed that excessive mortality would occur before termination of the study, based on the pattern of mortality, weight changes, and the general condition of mice used in similar studies on other chemicals at Gulf South Research Institute.

^cWhen test diets were discontinued, treated and control mice were fed control diets (2% corn oil added).

^dTime-weighted average dose = $\frac{\Sigma}{\Sigma}$ (dose in ppm x no. of weeks at that dose) $\frac{\Sigma}{\Sigma}$ (no. of weeks receiving each dose)

than picloram were also conducted at Gulf South Research Institute and overlapped the picloram study by at least 1 year. The matched-control groups for the different test chemicals were of the same strain and from the same supplier, and they were examined by the same pathologists.

G. Clinical and Pathologic Examinations

All animals were observed twice daily for signs of toxicity, weighed at regular intervals, and palpated for masses at each weighing. Animals that were moribund at the time of clinical examination were killed and necropsied.

The pathologic evaluation consisted of gross and microscopic examination of major tissues, major organs, and all gross lesions from killed animals and from animals found dead. The following tissues were examined microscopically: skin, lungs and bronchi, trachea, bone and bone marrow, spleen, lymph nodes, heart, salivary gland, liver, gallbladder (mice), pancreas, stomach, small intestine, large intestine, kidney, urinary bladder, pituitary, adrenal, thyroid, parathyroid, mammary gland, prostate or uterus, testis or ovary, and brain. Occasionally, additional tissues were also examined microscopically. The different tissues were preserved in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin.

Special staining techniques were utilized when indicated for more definitive diagnosis.

A few tissues from some animals were not examined, particularly from those animals that died early. Also, some animals were missing, cannibalized, or judged to be in such an advanced state of autolysis as to preclude histopathologic evaluation. Thus, the number of animals from which particular organs or tissues were examined microscopically varies, and does not necessarily represent the number of animals that were placed on study in each group.

H. Data Recording and Statistical Analyses

Pertinent data on this experiment have been recorded in an automatic data processing system, the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, clinical observations, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969). Data tables were generated for verification of data transcription and for statistical review.

These data were analyzed using the statistical techniques described in this section. Those analyses of the experimental

results that bear on the possibility of carcinogenicity are discussed in the statistical narrative sections.

Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's methods for testing for a dose-related trend. One-tailed P values have been reported for all tests except the departure from linearity test, which is only reported when its two-tailed P value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site is examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions prior to histologic sampling (e.g., skin or mammary tumors), or when lesions could have

appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a significantly higher proportion of tumors than did the control animals. As a part of these analyses, the one-tailed Fisher exact test (Cox, 1970) was used to compare the tumor incidence of a control group with that of a group of treated animals at each dose level. When results for a number of treated groups (k) are compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 may be made. The Bonferroni inequality (Miller, 1966) requires that the P value for any comparison be less than or equal to 0.05/k. In cases where this correction was used, it is discussed in the narrative section. It is not, however, presented in the tables, where the Fisher exact P values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971), was also used. Under the assumption of a linear trend, this test determines if the slope of the dose-response curve is different from zero at the onetailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend is a positive dose relation-

ship. This method also provides a two-tailed test of departure from linear trend.

A time-adjusted analysis was applied when numerous early deaths resulted from causes that were not associated with the formation of tumors. In this analysis, deaths that occurred before the first tumor was observed were excluded by basing the statistical tests on animals that survived at least 52 weeks, unless a tumor was found at the anatomic site of interest before week 52. When such an early tumor was found, comparisons were based exclusively on animals that survived at least as long as the animal in which the first tumor was found. Once this reduced set of data was obtained, the standard procedures for analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage tests, etc.) were followed.

When appropriate, life-table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which animals died naturally or were sacrificed was entered as the time point of tumor observation. Cox's methods of comparing these curves were used for two groups; Tarone's extension to testing for linear trend was used for three groups. The statistical tests for the incidence of tumors which used life-table methods were one-tailed and, unless otherwise

noted, in the direction of a positive dose relationship. Significant departures from linearity (P < 0.05, two-tailed test) were also noted.

The approximate 95 percent confidence interval for the relative risk of each treated group compared to its control was calculated from the exact interval on the odds ratio (Gart, 1971). The relative risk is defined as p_t/p_c where p_t is the true binomial probability of the incidence of a specific type of tumor in a treated group of animals and p_c is the true probability of the spontaneous incidence of the same type of tumor in a control group. The hypothesis of equality between the true proportion of a specific tumor in a treated group and the proportion in a control group corresponds to a relative risk of unity. Values in excess of unity represent the condition of a larger proportion in the treated group than in the control.

The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical analyses. The interpretation of the limits is that in approximately 95% of a large number of identical experiments, the true ratio of the risk in a treated group of animals to that in a control group would be within the interval calculated from the experiment. When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically

significant result (a P < 0.025 one-tailed test when the control incidence is not zero, P < 0.050 when the control incidence is zero) has occurred. When the lower limit is less than unity, but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit indicates that there is a theoretical possibility of the induction of tumors by the test chemical, which could not be detected under the conditions of this test.

III. <u>RESULTS - RATS</u>

A. Body Weights and Clinical Signs (Rats)

The mean body weights of the rats fed picloram were slightly lower than those of the matched controls until week 16 (figure 1). For the remainder of the study, however, the weights of the matched controls, particularly the males, were increasingly lower than those of the treated groups.

During the first 6 months of the study, the treated rats were generally comparable to the controls in appearance and behavior. During the second 6 months, clinical signs including diarrhea, hematuria, and rough hair coats were observed at a moderate incidence. At week 35 a few animals in each group, treated and matched-control, had an enlarged and protruding eyeball with a developing opacity of the corneal surface, and in some cases a definite thickening of the palpebral conjunctival membranes; this condition was diagnosed as viral conjunctivitis and left affected animals blind. This disease was considered to be incidental in the colony and was not related to treatment with picloram.

During the second year of the study, clinical signs were observed with an increased frequency in the treated rats. These signs




Figure 1. Growth Curves For Rats Fed Picloram In The Diet

included pale mucous membranes, dermatitis, alopecia, tachypnea, discolored (dark) urine, diarrhea, and vaginal bleeding.

B. Survival (Rats)

The Kaplan and Meier curves estimating the probabilities of survival for male and female rats receiving picloram at the doses of this experiment, together with those of the matched controls, are shown in figure 2. In both sexes, the Tarone test results for positive dose-related trend in mortality over the period are not significant at the 0.05 level. In male rats, 49% of the high-dose group, 68% of the low-dose group, and 50% of the matched-control group lived to the end of the study. Deaths in the high-dose group which occurred prior to termination of the study were not tumor associated. In females, survivals among the three groups are comparable; 69% of the high-dose group, 66% of the low-dose group, and 70% of the controls lived to the end of the study. Survival was adequate for meaningful statistical analyses of the incidences of tumors in these groups.

C. Pathology (Rats)

Histopathologic findings on neoplasms in rats are summarized in Appendix A, tables Al and A2; findings on nonneoplastic lesions are summarized in Appendix C, tables Cl and C2.




Figure 2. Survival Curves For Rats Fed Picloram In The Diet

Similar lesions occurred among animals of the matched-control and treated groups. For the most part, these lesions are commonly encountered in aging rats of the Osborne-Mendel strain. Furthermore, the incidence in which they occurred in treated rats was similar to that in which they were observed to occur spontaneously in similar studies. However, there was а relatively high incidence of follicular and C-cell hyperplasia and/or neoplasia of the thyroid gland, neoplastic nodules of the liver, and cellular alteration of the liver exclusively or almost exclusively in picloram-treated rats. The neoplastic nodules were composed predominantly of eosinophilic hepatocytes and lesser numbers of clear hepatocytes. Foci of cellular alteration composed of eosinophilic and/or clear hepatocytes were seen in the livers of several treated rats. The significance of these changes in both the thyroid and the liver is difficult to assess because of the disproportionately small number of matched-control animals.

Although neoplastic nodules and foci of cellular alteration were observed in the liver of only treated male and female rats and may have been treatment related, in the judgment of the pathologist, there was no conclusive evidence of carcinogenicity induced by picloram in Osborne-Mendel rats at the doses administered and for the period of time rats were fed in this study.

D. Statistical Analyses of Results (Rats)

Tables El and E2 in Appendix E contain the statistical analyses of the incidences of those specific primary tumors that were observed in at least 5% of one or more treated groups of either sex.

In the analyses of the incidence of neoplastic nodule of the liver in female rats, the Cochran-Armitage test result for positive dose-related trend in proportions is significant (P = 0.016) using the pooled controls, and the Fisher exact test shows a significantly higher incidence of this tumor in the high-dose group (P = 0.014) when compared with the pooled controls. The statistical conclusion is that the occurrence of neoplastic nodule of the liver in female rats is associated with picloram at the doses administered in this experiment. The statistical test results of the incidence of this tumor in male rats are not significant at the 0.05 level.

In female rats, although the Cochran-Armitage test result for positive dose-related trend in proportions for C-cell adenoma of the thyroid is significant (P = 0.029) using the pooled controls, the Fisher exact test for comparisons of the incidences in the treated groups with those in the control groups do not confirm

this result. Statistical tests of the incidence of this tumor in male rats are not significant at the 0.05 level.

There are no other tumors for which the statistical test results of the incidences are significant in the positive direction. In all of the confidence intervals shown in the tables for the incidences of tumors, other than those in the liver, the value of one or less than one is included, indicating the absence of significant positive results. It should also be noted that these intervals, except the incidence of chromophobe adenoma of the pituitary in low-dose male rats, have upper limits greater than one, indicating the theoretical possibility of the induction of tumors by picloram, which could not be detected under the conditions of this test. Elimination of those animals dying before week 52 on study does not affect the conclusions of this analysis.

IV. RESULTS - MICE

A. Body Weights and Clinical Signs (Mice)

The mean body weights of the treated male and female mice were essentially unaffected by the picloram over the period of the bioassay (figure 3).

During the first 16 weeks of the study, the treated mice were generally comparable to the controls in appearance and behavior. At week 17, one low-dose female and five high-dose females had generalized body tremors. During the remainder of the first year, the general condition of both treated and control mice was good. A few individual animals lost weight, and had alopecia and fight wounds.

During the second year of the study, clinical signs were noted with increasing frequency among the treated mice. At week 52, a majority of treated males appeared to be slightly hyperactive. Rough hair coats were observed in low-dose males beginning at week 57 and in high-dose males beginning at week 68 and continuing to termination of the study. Other clinical signs included abdominal distention, predominantly among the low-dose males and females.




Figure 3. Growth Curves For Mice Fed Picloram In The Diet

B. <u>Survival (Mice)</u>

The Kaplan and Meier curves estimating the probabilities of survival for male and female mice receiving picloram at the doses of this experiment, together with those of the matched controls, are shown in figure 4. In neither sex was the Tarone test result significant at the 0.05 level for positive dose-related trend in mortality over the period. With over 80% of both male and female groups living to termination of the study, survival was adequate for meaningful statistical analyses of the incidences of late-developing tumors.

C. Pathology (Mice)

Histopathologic findings on neoplasms in mice are summarized in Appendix B, tables Bl and B2; findings on nonneoplastic lesions are summarized in Appendix D, tables Dl and D2.

Neoplastic and nonneoplastic lesions were found in mice of the treated and matched-control groups. The lesions occurred with a wide variation, random distribution, and either in insignificant numbers or with approximately equal frequency among mice of the treated and control groups.

In the judgment of the pathologist, there was no conclusive evidence of carcinogenicity induced by picloram in the B6C3F1




Figure 4. Survival Curves For Mice Fed Picloram In The Diet

hybrid mouse at the doses administered and for the period of time mice were fed in this study.

D. Statistical Analyses of Results (Mice)

Tables Fl and F2 in Appendix F contain the statistical analyses of the incidences of those specific primary tumors that were observed in at least 5% of one or more treated groups of either sex.

In neither sex were the results of the Cochran-Armitage test for positive dose-related trend in proportions or the Fisher exact test for comparisons of incidences between the treated groups and the control groups significant at the 0.05 level. In all of the 95% confidence intervals shown in the tables for the incidence of tumors, the lower limit has a value of less than one, indicating the absence of positive significant results. It should also be noted that these intervals have upper limits greater than one, indicating the theoretical possibility of the induction of tumors by picloram, which could not be detected under the conditions of this test.

V. DISCUSSION

In this bioassay, picloram did not consistently affect the body weights of the treated animals. Mean body weights of high-dose rats were lower than those of the matched controls early in the study, but beginning at approximately 80 weeks, mean weights of controls were lower than those of the treated animals.

Body weights of mice were unaffected by picloram. No consistent clinical signs attributable to treatment were reported during the first 6 months of the study, except for isolated incidences of tremors and hyperactivity in mice. Later, particularly during the second year, rough hair coats, diarrhea, pale mucous membranes, alopecia, and abdominal distention occurred in both treated rats and mice to a greater degree than in the controls.

Survival was adequate for meaningful statistical analyses of the incidences of tumors in groups of rats and mice of both sexes.

In rats, a relatively high incidence of follicular hyperplasia, C-cell hyperplasia, and C-cell adenoma of the thyroid occurred in both sexes. However, the statistical tests for adenoma did not show sufficient evidence for association of the tumor with picloram administration.

An increased incidence of hepatic neoplastic nodules was observed

in treated male and female rats as compared with untreated animals. This lesion is considered to be a benign tumor. In male rats the lesion appeared only in three animals of the low-dose treatment group and was not significant when compared with the controls; however, the test for positive dose-related trend in females was significant (pooled controls 0/39, low-dose 5/50, high-dose 7/49, P = 0.016), and the incidence in the high-dose group was significant (P = 0.014) when compared with that in the pooled-control group.

There was also one hepatocellular carcinoma in a low-dose male rat and one in a high-dose female rat. In both males and females, there was a possibly treatment-related lesion of the liver diagnosed as foci of cellular alteration. These latter lesions are frequently associated with the induction of neoplastic nodules and hepatocellular carcinomas in rats (Squire and Levitt, 1975). The incidences of the foci were, female rats: matched controls 1/10, low-dose 8/50, high-dose 18/49; male rats: matched controls 0/10, low-dose 12/49, high-dose 5/49. Thus, there is evidence that picloram affected the livers of rats of both sexes, but more particularly those of the females.

In mice, no tumors occurred in proportions that could be shown to be related to the administration of picloram, either by tests for

dose-related trend or by direct comparisons of the incidences in treated and control groups.

In previous studies of the toxicity of picloram, Lynn (1965) reported $LD_{50}s$ of 2,000 to 4,000 mg/kg in the female mouse and over 8,000 mg/kg in the female rat. McCollister and Leng (1969) reported no adverse effects or tumors in albino rats and Beagle dogs at intakes up to 150 mg/kg/day for 2 years. Intakes of 150 mg/kg/day are lower than the doses used for rats in the present bioassay.

No tumors were found in male or female mice or male rats at incidences that could be significantly associated with treatment, and it is concluded that picloram was not carcinogenic for B6C3F1 mice or male Osborne-Mendel rats.

In female rats, however, the incidence of neoplastic nodules of the liver, benign tumors, was associated with treatment with picloram. It is concluded that under the conditions of the bioassay, the findings are suggestive of the ability of the compound to induce benign tumors in the livers of female Osborne-Mendel rats.

VI. BIBLIOGRAPHY

- Armitage P., <u>Statistical Methods in Medical Research</u>, John Wiley & Sons, Inc., New York, 1971, pp. 362-365.
- Berenblum, I., ed., <u>Carcinogenicity Testing</u>: <u>A Report of the</u> <u>Panel on Carcinogenicity of the Cancer Research Commission</u> <u>of the UICC, Vol.2</u>, International Union Against Cancer, Geneva, 1969.
- Bradley, R. T., Shoemaker, J. P. and Hoffman, R. V., Jr., Treatment of Experimental Mammary Adenocarcinoma with Herbicides. <u>Cancer Chemother. Rep.</u> 58:745-748, 1974.
- Cox, D. R., Regression models and life tables. J. R. Statist. Soc. <u>B</u> 34:187-220, 1972.
- Cox, D. R., <u>Analysis of Binary Data</u>, Methuen & Co., Ltd., London, 1970, pp. 48-52.
- Edwards, C. A., <u>Persistent Pesticides in the Environment</u>, 2nd edition, CRC Press, Cleveland, Ohio, 1976.
- Environmental Protection Agency, <u>EPA Compendium of Registered</u> <u>Pesticides</u>, U. S. Government Printing Office, Washington, D. C., I-P-16.1 - I-P-16.3, 1974.
- Gart, J. J., The comparison of proportions: a review of significance tests, confidence limits and adjustments for stratification. <u>Rev. Int. Stat. Inst. 39</u>:148-169, 1971.
- Hamaker, J. W., Johnston, H., Martin, R. T., and Redemann, C. T., A picolinic acid derivative: a plant growth regulator. <u>Science 141</u>:363, 1963.
- Kaplan, E. L. and Meier, P., Nonparametric estimation from incomplete observations. <u>J. Am. Statist. Assoc.</u> 53:457-481, 1958.
- Linhart, M. S., Cooper, J. A., Martin, R. L., Page, N. P., and Peters, J. A., Carcinogenesis bioassay data system. <u>Comp.</u> <u>and Biomed. Res.</u> 7:230-248, 1974.
- Lynn, G. E., A review of toxicological information on Tordon herbicides. <u>Down to Earth 20</u> (4):6-8, 1965.

- McCollister, D. D. and Leng, M. L., A review of agricultural chemical progress. Down to Earth 25 (2):5-10, 1969.
- Miller, R. G., Jr., <u>Simultaneous Statistical Inference</u>, McGraw-Hill Book Co., New York, 1966, pp. 6-10.
- Neumeyer, J., Herbicides. In: <u>The Encyclopedia of Chemistry</u>, 3rd edition, Hampel, C. A. and Hawley, G. G., eds., Van Nostrand Reinhold, New York, 1973, pp. 526-529.
- Saffiotti, U., Montesano, R., Sellakumar, A. R., Cefis, F., and Kaufman, D. G., Respiratory tract carcinogenesis in hamsters induced by different numbers of administrations of benzo(a) pyrene and ferric oxide. <u>Cancer Res</u> <u>32</u>:1073-1081, 1972.
- Spencer, E. Y., <u>Guide to Chemicals Used in Crop Protection</u>, Research Institute, University of Western Ontario, London, Ontario, 1973, p. 414.
- Squire, R. A. and Levitt, M. H., Report of a workshop on classification of specific hepatocellular lesions in rats. <u>Cancer Res.</u> <u>35</u>: 3214-3223, 1975.
- Tarone, R. E., Tests for trend in life table analysis. <u>Biometrika 62 (3)</u>:679-682, 1975.

APPENDIX A

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN

RATS FED PICLORAM IN THE DIET

TABLE A1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS
FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
ANIMAIS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	10 10 10	50 50 50 50	50 50 49
*SKIN BASAL-CELL CARCINOMA	(10)	(50) 1 (2%)	(50)
*SUBCUT TISSUE FIBRCMA FIBROUS HISTIOCYTOMA	(10)	(50)	(50) 1 (2%) 1 (2%)
ESPIRATORY SYSTEM			
<pre>#LU NG UNCIFFERENTIATED CARCINOMA METAS PHEOCHROMOCYTOMA, METASTATIC</pre>	(10)	(49)	(50) 1 (2%) 1 (2%)
IEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS MALIG.LYMPHOMA, UNDIFFER-TYPE LYMPHOCYTIC LEUKEMIA	(10)	(50) 1 (2%)	(50) 1 (2%)
*SPLEEN UNCIFFERENTIATED CARCINOMA METAS HEMANGIOMA	(10)	(50) 3 (6%)	(50) 1 (2%) 1 (2%)
CIRCULATORY SYSTEM			
#HEART <u>FIBRCMA</u>	(10)	(49)	(50)

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
)IGESTIVE SYSTEM			
#LIVER UNDIFFERENTIATED CARCINOMA METAS NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA FIBROSARCOMA	(10)	(49) 3 (6%) 1 (2%) 1 (2%)	(49) 1 (2%)
*BILE DUCT BILE DUCT ADENOMA	(10)	(50)	(50) 1 (2%)
*PANCREAS UNDIFPERENTIATED CARCINOMA	(10)	(49)	(49) 1 (2%)
*STCMACH UNDIFFERENTIATED CARCINOMA METAS PAPILLOMA, NOS	(10)	(50)	(46) 1 (2%) 1 (2%)
JRINARY SYSTEM			
*KIDNEY TUBULAR-CELL ADENOMA	(10)	(5 0)	(50) 1 (2%)
ENDOCRINE SYSTEM			
<pre>#PITUITARY CARCINCMA,NOS CHROMOPHOBE ADENOMA</pre>	(9) 2 (22%)	(46) 2 (4%) 2 (4%)	(45) 9 (20%
<pre>#ADRENAL CCRTICAL ADENCMA PHEOCHROMOCYTOMA, MALIGNANT</pre>	(10)	(49) 2 (4%)	(49) 1 (2%)
*THYROID C-CELL ADENOMA C-CELL CARCINOMA	(9)	(47) 6 (13%)	(49) 1 (2%) 1 (2%)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND FIBRCMA	(10) 1 (10%)	(50) 1 (2%)	(50) 1 (2%)
NERVOUS SYSTEM			
#BRAIN MENINGIOMA	(19)	(49) <u>1_(2%)</u>	(50)

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

* NUMBER OF ANIMALS NECROPSIED

.

	CONTROL	LOW DOSE	HIGH DOSI
PECIAL SENSE ORGANS			
NONE			
USCULOSKELETAL SYSTEM			
NONE			
ODY CAVITIES			
*ABDCMINAL CAVITY UNDIFFERENTIATED CARCINOMA METAS	(10)	(50)	(50) 1 (2%)
* MESENTERY UNDIFFERENTIATED CARCINOMA METAS	(10)	(50)	(50) 1 (2%
LL CTHER SYSTEMS			
*MULTIPLE ORGANS FIBROUS HISTIOCYTOMA, MALIGNANT	(10)	(50) 1 (2%)	(50) 1 (2 %
DIAPHRAGM UNCIFFERENTIATED CARCINOMA METAS			1
NIMAL DISPOSITION SUMMARY			
	10	50	50
NATURAL DEATHƏ Moribund sacrifice Scheduled sacrifice	5	6 11	10 16
ACCIDENTALLY KILLED Terminal sacrifice Animal missing	5	33	24
INCLUDES AUTOLYZED ANIMALS			***

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* TOTAL PRIMARY TUMORS	3 3	2 3 26	18 22
TOTAL ANIMALS WITH BENIGN TUMORS TCTAL BENIGN TUMORS	3 3	14 15	13 17
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS		8 8	5 5
TO TAL ANIMALS WITH SECONDARY TUMORS TOTAL SECONDARY TUMORS	*		2 8
TOTAL ANIMALS WITH TUMORS UNCERTAIN BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	-	3	
TCTAL ANIMALS WITH TUMORS UNCERTAIN PRIMARY CR METASTATIC TOTAL UNCEPTAIN TUMORS	-		
* PRIMARY TUMORS: ALL TUMORS EXCEPT S # SECONDAPY TUMORS: METASTATIC TUMORS			ADJACENT ORGAN

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
NIMALS INITIALLY IN STUDY NIMALS NECROPSIED NIMALS EXAMINED HISTOPATHOLOGICALLY	10 10 10	50 50 50 50	50 50 49
NTEGUMENTARY SYSTEM			
*SUBCUT TISSUE	(10)	(50)	(50)
SARCCMA, NOS FIBROUS HISTIOCYTOMA	1 (10%)		1 (2%)
ESPIRATCRY SYSTEM			
#L UNG	(10)	(50)	(49)
LIPOSARCCMA, METASTATIC			1 (2%)
OSTEOSARCOMA, METASTATIC		1 (2%)	
EMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS LYMPHOCYTIC LEUKEMIA	(10) 1 (10%)	(50)	(50) 1 (2%)
IFCULATCRY SYSTEM			
NONE			
IGESTIVE SYSTEM			
#LIVER NEOPLASTIC NODULE	(10)	(50) 5 (10%)	(49) 7 (14%)
HEPATOCELLULAR CARCINOMA		J (10A)	1 (2%)
RINARY SYSTEM			
#KIDNEY	(10)	(48)	(48)
LIPCSARCOMA <u>tHAMARTOMA</u>		1 (2%)	1 (2%) 1 (2%)

* NUMBER OF ANIMALS NECROPSIED

† This is considered to be a benign form of the malignant mixed tumor of the kidney and consists of lipocytes, tubular structures, and fibroblasts in varying proportions.

	CONTPOL	LOW DOSE	HIGH DOSE
NDOCRINE SYSTEM			
<pre>#PITUITARY</pre>	(9)	(48)	(46)
CARCINCMA, NOS	1 (11%)	1 (2%)	
ADENOMA, NOS Chromophobe adenoma		7 (15%)	7 (15%)
#ADRENAL	(8)	(50)	(48)
CCRTICAL ADENOMA	• •	2 (4%)	4 (8%)
PHEOCHROMOCYTOMA OSTEOSARCOMA, METASTATIC		1 (2%)	1 (2%)
#THYROID	(9)	(46)	(46)
C-CELL A DENOMA	(-)	3 (7%)	7 (15%)
<pre>#PANCREATIC ISLETS ISLET-CELL ADENOMA</pre>	(10)	(47) 1 (2%)	(49) 1 (2%)
REPRODUCTIVE SYSTEM *MAMMAPY GLAND INFILTRATING DUCT CARCINOMA FIBROMA FIBROADENOMA	(10) 1 (10%)	(50) 1 (2%) 1 (2%) 6 (12%)	(50) 1 (2%) 2 (4%) 4 (8%)
#UTERUS	(10)	(48)	(45)
SQUAMOUS CELL CARCINOMA GRANULOSA-CELL CARCINOMA, METAST		1 (2%) 1 (2%)	
ENDOMETRIAL STROMAL POLYP ENDOMETRIAL STROMAL SARCOMA	1 (10%)	8 (17%)	4 (9%) 1 (2%)
#UTERUS/ENDOMETRIUM A DENCCARCINOMA, NOS	(10)	(48) 1 (2%)	(45)
# OV A RY	(10)	(47)	(48)
GRANULOSA-CELL CARCINOMA		1 (2%)	
*BRAIN	(10)	(50)	(49)
GRANULAR-CELL TUMOR, BENIGN	(10)		1 (2%)
GRANULAR-CELL TUMOR, MALIGNANT		1 (2%)	

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY # NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSI
SPECIAL SENSE ORGANS			
NONE			
USCULOSKELETAL SYSTEM			
*SHOULDER JOINT CSTECSARCOMA	(10)	(50) 1 (2%)	(50)
BODY CAVITIES			
*MESENTERY GRANULOSA-CELL CARCINOMA, METAST	(10)	(50) 1 (2%)	(50)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS PIBRCUS HISTIOCYTOMA, MALIGNANT	(10)	(50) 1 (2%)	(50)
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	10	50	50
NATURAL DEATHD	1	2	4
MORIBUND SACRIFICE SCHEDULED SACRIFICE	2	15	11
ACCIDENTALLY KILLED			1
TERMINAL SACRIFICE Animal Missing	7	33	34
<u>@ INCLUDES AUTOLYZED ANIMALS</u>			

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
TUNOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* TCTAL FRIMARY TUMORS	5 5	32 43	30 46
TOTAL ANIMALS WITH BENIGN TUMORS TOTAL BENIGN TUMORS	2 2	2 5 30	23 33
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	3 3	6 8	6 6
TOTAL ANIMALS WITH SECONDARY TUMORS TOTAL SECONDARY TUMORS	ŧ	2 4	1 1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	-	5 5	ר ר
TCTAL ANIMALS WITH TUMORS UNCERTAIN PRIMARY CR METASTATIC TOTAL UNCERTAIN TUMORS	-		
PRIMARY TUMORS: ALL TUMORS EXCEPT SI SECONDARY TUMORS: METASTATIC TUMORS			DJACENT ORGAN

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

APPENDIX B

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN

MICE FED PICLORAM IN THE DIET

TABLE B1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	10	50	50
NIMALS NECROPSIED NIMALS EXAMINED HISTOPATHOLOGICALLY	10 10	50 50	49 49
NTEGUMENTARY SYSTEM			
*SKIN SARCCMA, NOS	(10)	(50) 1 (2%)	(49)
ESPIRATORY SYSTEM			
#LUNG ALVECLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	(10) 1 (10%)	(49) 4 (8%) 1 (2%)	(48) 2 (4 %) 1 (2 %)
IEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS MALIG.LYMPHOMA, HISTIOCYTIC TYPE LYMPHOCYTIC LEUKEMIA	(10)	(50)	(49) 1 (2%) 1 (2%)
CIRCULATORY SYSTEM			
NONE			
DIGESTIVE SYSTEM			
*LIVER	(10)	(49)	(49)
HEPATOCELLULAR ADENOMA NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	1 (10%) 4 (40%)	2 (4%) 11 (22%)	2 (4%) 2 (4%) 4 (8%)
URINARY SYSTEM			
NONE			

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
ENDOCRINE SYSTEM			
#THYROID FCLLICULAR-CELL ADENOMA	(10)	(48)	(44) 2 (5%)
EPRODUCTIVE SYSTEM			
#TESTIS INTERSTITIAL-CELL TUMOR SEMINOMA/LYSGERMINOMA	(10) 1 (10%)	(48)	(48) 1 (2%)
NERVCUS SYSTEM			
NONE			
SPECIAL SENSE ORGANS			
*EYE/LACRIMAL GLAND PAPILLARY ADENOMA	(10)	(50)	(49) 1 (2%)
IUS CULOS KELETAL SYSTEM			
NONE			
BODY CAVITIES			
NONE			
ALL OTHER SYSTEMS			
NON E			

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
NIMAL DISPOSITION SUMMARY			
ANIMAIS INITIALLY IN STUDY	10	50	50
NATURAL DEATHO	_	_	3
MORIBUND SACRIFICE	1	7	7
SCHEDULED SACRIFICE Accidentally killed			
TERMINAL SACRIFICE	9	43	40
ANIMAL MISSING			
INCLUDES AUTOLYZED ANIMALS			
UNCR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS*	5	18	14
TOTAL PRIMARY TUMORS	7	19	17
TOTAL ANIMALS WITH BENIGN TUMORS	2	4	4
TOTAL BENIGN TUMORS	2	4	7
TOTAL ANIMALS WITH MALIGNANT TUMORS	4	13	8
TCTAL MALIGNANT TUMORS	4	13	8
TOTAL ANIMALS WITH SECONDARY TUMORS	ŧ		
TOTAL SECONDARY TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN-	-		
BENIGN OR MALIGNANT	1	2	2
TOTAL UNCERTAIN TUMORS	1	2	2
TOTAL ANIMALS WITH TUMORS UNCERTAIN	-		
PRIMARY CR METASTATIC			
TOTAL UNCERTAIN TUMORS			
PRIMARY TUMORS: ALL TUMORS EXCEPT SI	CONDARY TUM	DRS	

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

TABLE B2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOS E
ANIMALS INITIALLY IN STUDY ANIMAIS NECROPSIED ANIMAIS EXAMINED HISTOPATHOLOGICALLY	10 10 10	50 49 49	50 50 50
INTEGUMENTARY SYSTEM			
NONE	• • • • • • • • • • • • • • • • • • •		
RESFIRATCRY SYSTEM			
#LUNG ALVECLAR/BRUNCHIOLAR ADENOMA OSTEOSARCOMA	(10) 1 (10%)	(49) 1 (2%) 1 (2%)	(50)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS IYMPHCCYTIC LEUKENIA	(10)	(49) 2 (4%)	(50)
CIRCULATORY SYSTEM			
NONE			
DIGESTIVE SYSTEM			
#LIVER HEPATOCELLULAR CARCINOMA		(49)	1 (2%)
URINARY SYSTEM			
NON E			
ENDOCRINE SYSTEM			
<pre>#THYROID POLLICULAR-CELL_ADENOMA</pre>	(10)	(47) <u>1_(2%)</u>	(45) <u>1 (2%)</u>
<pre># NUMBER OF ANIMALS WITH TISSUE EXAMI * NUMBER OF ANIMALS NECROPSIED</pre>			

	CONTROL	LOW DOSE	HIGH DOSE
EPRCCUCTIVE SYSTEM			
*MAMMARY GLAND ADENOCARCINOMA, NOS	(10)	(49) 1 (2%)	(50) 1 (2 %)
ERVOUS SYSTEM			
NONE			
PECIAL SENSE ORGANS			
NONE			
US CULOS KELETAL SYSTEM			
NONE			
ODY CAVITIES			
NONE			
ILL OTHER SYSTEMS			
NONE			
NIMAL DISFOSITICN SUMMARY			
ANIMALS INITIALLY IN STUDY	10	50	50
NATURAL DEATHƏ Moribund sacrifice Scheduled sacrifice		27	3
ACCIDENTALLY KILLED TERMINAL SACRIFICE ANIMAL MISSING	10	41	47
INCLUDES AUTOLYZED ANIMALS			

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* TCTAL PRIMARY TUMORS	1 1	6 6	3 3
TOTAL ANIMALS WITH BENIGN TUMORS TOTAL BENIGN TUMORS	1 1	2 2	1 1
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	:	4 4	2 2
TOTAL ANIMALS WITH SECONDARY TUMORS TOTAL SECONDARY TUMORS	5#		
TOTAL ANIMALS WITH TUMORS UNCERTAIN BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	-		
TOTAL ANIMALS WITH TUMORS UNCERTAIN PRIMARY CR METASTATIC TOTAL UNCERTAIN TUMORS	1-		
* PPIMARY TUMORS: ALL TUMORS EXCEPT S * SECONDARY TUMORS: METASTATIC TUMORS			DJACENT ORGAN

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

APPENDIX C

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS

IN RATS FED PICLORAM IN THE DIET

TABLE C1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS FED PICLORAM IN THE DIET

50 50 50 (50) (50) 1 (2%) 1 (2%) 1 (2%) (49) 0%)	50 50 49 (50) 1 (2%) (50) (50)
50 (50) 0%) 1 (2%) (50) 1 (2%) 1 (2%) (49)	49 (50) 1 (2%) (50) 1 (2%)
(50) 0%) 1 (2%) (50) 1 (2%) 1 (2%) (49)	(50) 1 (2%) (50) 1 (2%)
0%) 1 (2%) (50) 1 (2%) 1 (2%) (49)	(50) 1 (2%)
0%) 1 (2%) (50) 1 (2%) 1 (2%) (49)	(50) 1 (2%)
(50) 1 (2%) 1 (2%) (49)	(50) 1 (2%)
(50) 1 (2%) 1 (2%) (49)	1 (2%)
1 (2%) 1 (2%) (4 9)	1 (2%)
1 (2%) (49)	
(4 9)	(50)
	(50)
(50)	(50)
1 (2%)	
2 (4%)	1 (2%)
(44)	(45)
0%)	
0%)	
(49)	(50)
1 (25)	1 (2%)
· \/	(50)
-	1 (2%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
#MYOCARDIUM PIBROSIS, FOCAL PIBROSIS, DIFFUSE CALCIFICATION, NOS CALCIFICATION, FOCAL	(10) 1 (10%)	(49) 3 (6%) 1 (2%)	(50) 4 (8\$) 2 (4\$) 1 (2\$) 1 (2\$)
*AORTA MPDIAL CALCIFICATION	(10)	(50)	(50) 3 (6 %)
*CORONARY ARTERY ARTERIOSCLEROSIS, NOS	(10) 1 (10%)	(50)	(50)
DIGESTIVE SYSTEM			
<pre>#LIVER INFLAMMATION, FOCAL GRANULOMATOU METAMORPHOSIS FATTY FOCAL CELLULAR CHANGE</pre>	(10) 2 (20%)	(49) 1 (2%) 12 (24%)	(49) 9 (18% 5 (10%
*BILE DUCT INFLAMMATION, CHRONIC FOCAL HYPERPLASIA, NOS HYPERPLASIA, FOCAL HYPERPLASIA, DIFFUSE	(10)	(50) 1 (2 %)	(50) 1 (2%) 1 (2%) 2 (4%)
<pre>#PA NC REA S ARTERICSCLEROSIS, NOS</pre>	(10)	(49)	(49) 1 (2%)
<pre>#PANCREATIC ACINUS ATROPHY, NOS</pre>	(10)	(49)	(49) 1 (2%)
#STCMACH ULCER, NOS BROSION CALCIFICATION, NOS	(10)	(50) 1 (2%)	(46) 1 (2%) 1 (2%) 4 (9%)
#GASTRIC MUCOSA CALCIFICATION, NOS	(10)	(50)	(46) 1 (2%)
#GASTRIC MUSCULARIS CALCIFICATION, NOS	(10)	(50) 1 (2 %)	(46)
#CECUM INFLAMMATION, ACUTE	(6)	(41)	(40)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY # NUMBER OF ANIMALS NECROPSIED

TABLE C1. MALE RATS:	NONNEOPLASTIC LESIONS	(CONTINUE	D)	

.

	CONTROL	LOW DOSE	HIGH DOSI
IRINARY SYSTEM			
#KIDNEY	(10)	(50)	(50)
CALCULUS, NOS	2 (20)	1 (2%)	
GLOMERULONEPHRITIS, NOS Pyelonephritis, Acute	3 (30%)	1 (2%)	
INFLAMMATION, CHRONIC	5 (50%)	12 (24%)	26 (52%
NEPHROSIS, NOS		1 (2%)	
#URINARY BLADDER	(9)	(47)	(46)
INFLAMMATICN, ACUTE SUPPURATIVE		1 (2%)	
NDOCRINE SYSTEM			
#PITUITARY	(9)	(46)	(45)
CYST, NOS		4 (9%)	10 (229
HEMORRHAGE		4 (20)	1 (2%)
DEGENERATION, CYSTIC Hyperplasia, focal	1 (11%)	1 (2%) 1 (2%)	2 (4%)
HIERELASIA, FOCAL	, (,,,,,,	1 (2%)	
#ADRENAL	(10)	(49)	(49)
CYST, NOS		1 (2%)	
HEMORRHAGE	1 (100)	1 (2%)	1 (2%)
DEGENERATION, CYSTIC Metamorphosis fatty	1 (10%)	2 (4%) 1 (2%)	1 (2%)
ANGIECTASIS		1 (2%)	(2,4)
#ADRENAL CORTEX	(10)	(49)	(49)
DEGENERATION, NOS		2 (4%)	
DEGENERATION, CYSTIC Metamorphosis Patty			1 (2%) 1 (2%)
HYPERPLASIA, FOCAL		3 (6%)	2 (4%)
		5 (0N)	- ()
#THY ROID	(9)	(47)	(49)
CYSTIC FOLLICLES		6 .	1 (2%)
HYPERPLASIA, C-CELL		6 (13%)	7 (14%
HYPERPLASIA, FOLLICULAR-CELL		5 (11%)	6 (12%
#PARATHY ROID	(6)	(32)	(35)
HYPERPLASIA, NOS		1 (3%)	7 (20%
EPRODUCTIVE SYSTEM			
*MAMMARY GLAND ADENCSIS	(10)	(50)	(50)

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
<pre>#PROSTATE INFLAMMATION, SUPPURATIVE INFLAMMATION, ACUTE SUPPURATIVE INFLAMMATION ACUTE AND CHRONIC CONTENTS AND CHRONIC</pre>	(9)	(47) 2 (4%) 1 (2%)	(48) 1 (2%) 1 (2%) 1 (2%)
CALCIFICATION, NOS Atrophy, nos		1 (2%)	1 (2%)
<pre>#TESTIS PERIARTERITIS ATROPHY, NOS</pre>	(10) 5 (50%)	(50) 1 (2%) 7 (14%)	(50) 3 (6%) 14 (28%
IER VOUS SYSTEM			
NONE			
PECIAL SENSE ORGANS			
*EYE CATARACT	(10) 1 (10%)	(50)	(50)
USCULOSKFLETAL SYSTEM			
*BONE CSTECFOROSIS		(50)	(50) 1 (2%)
BODY CAVITIES			
*PIEURA INFLAMMATION, CHRONIC FOCAL	(10)	(50)	(50) 1 (2%)
*MESENTERY PERIARTERITIS ARTERIOSCLEROSIS, NOS	(10) 2 (20%) 1 (10%)	(50) 2 (4%)	(50) 7 (14% 1 (2%)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS PERIARTERITIS	(10)	(50)	(50)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
SPECIAL MCRPHOLOGY SUMMARY			
NC LESION REPORTED AUTO/NECROPSY/NO HISTO	1	11	2 1
# NUMBER OF ANIMALS WITH TISSUE EXA * NUMBER OF ANIMALS NECROPSIED	MINEL MICROSCO	PICALLY	

TABLE C2.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE	
ANIMALS INITIALLY IN STUDY	10	50	 50	
ANIMALS NECROPSIED	10	50	50	
ANIMALS EXAMINED HISTOPATHOLOGICALLY	10	50	49	
INTEGUMENTARY SYSTEM				
NON E				
RESPIRATCRY SYSTEM				
NONE				
HEMATOPOIETIC SYSTEM				
#SPLEEN	(10)	(49)	(49)	
HEMATOFOIESIS Myeloid metaplasia		. ,	1 (2%) 1 (2%)	
#SPLENIC RED PULP	(10)	(49)	(49)	
ATRCPHY, NOS		1 (2%)		
#CERVICAL LYMPH NODE INFLAMMATION, NOS	(8) 1 (13 %)	(46)	(46)	
CIRCULATORY SYSTEM				
#MYOCARDIUM	(10)	(50)	(49)	
FIBRCSIS, FOCAL		1 (2%)	1 (2%)	
DIGESTIVE SYSTEM				
#LIVER	(10)	(50)	(49)	
NECROSIS, FOCAL Metamorphosis Fatty		1 (2%)	2 (4%)	
FOCAL CELLULAR CHANGE	1 (10%)	8 (16%)	18 (37%)	
NYELOID METAPLASIA			<u> </u>	

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
*BILE DUCT FIBROSIS HYPERPLASIA, NOS HYPERPLASIA, FOCAL	(10)	(50) 2 (4%) 3 (6%) 1 (2%)	(50) 6 (12%) 1 (2%)
#PANCREATIC ACINUS ATROPHY, FOCAL	(10)	(47) 1 (2%)	(49)
#STCMACH ULCER, NOS	(10)	(49)	(48) 1 (2%)
URINARY SYSTEM			
<pre>#KIDNEY CYST, NOS INFLAMMATION, CHRONIC FIBROSIS, FOCAL</pre>	(10) 1 (10%)	(48) 1 (2%) 2 (4%)	(48) 4 (8%) 1 (2%)
ENDOCRINE SYSTEM			
*PITUITARY CYST, NOS CONGESTION, NOS HEMORRHAGE HYPERPLASIA, NOS	(9) 1 (11%) 1 (11%) 1 (11%) 1 (11%)	(48) 3 (6%)	(46) 1 (2 %)
HYPERPLASIA, FOCAL		1 (2%)	1 (2%)
#ADRENAL THROMBCSIS, NOS HEMORPHAGE DEGENERATION, CYSTIC	(8) 1 (13%)	(50) 5 (10%) 3 (6%)	(48) 5 (10%) 2 (4%)
#ADRENAL CORTEX HEMORRHAGE DEGENERATION, NOS DEGENERATION, CYSTIC HYPEPPLASIA, FOCAL	(8) 1 (13%)	(50) 2 (4%) 1 (2%) 2 (4%)	(48) 6 (13%) 1 (2%)
*THYROID HYPERPLASIA, C-CELL HYPERPLASIA, FOLLICULAR-CELL	(9)	(46) 8 (17%) <u>1 (2%)</u>	(46) 6 (13%) <u>6 (13%)</u>

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY # NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE	
REPROLUCTIVE SYSTEM				
*MAMMARY GLAND	(10)	(59)	(50)	
HYPERPLASIA, NOS Dysplasia, Nos		6 (12%) 1 (2%)	6 (12%)	
ADENOSIS	1 (10%)	,		
#UTERUS	(10)	(48)	(45)	
METAPLASIA, SQUAMOUS		1 (2%)		
#OVARY Cyst, Nos	(10)	(47) 1 (2%)	(48)	
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
* MESENTERY	(10)	(50)	(50)	
PERIARTERITI S			(50) 1 (2%)	
ALL OTHER SYSTEMS				
NONE				
SPECIAL MORPHOLOGY SUMMARY				
			_	
NO LESION REPORTED	2	8	7	

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

APPENDIX D

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS

IN MICE FED PICLORAM IN THE DIET

TABLE D1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE FED PICLORAM IN THE DIET

	CONTROL	LOW DOSE	HIGH DOSE
NIMALS INITIALLY IN STUDY NIMAIS NECROPSIED NIMALS EXAMINED HISTOPATHOLOGICALLY	10 10 10	50 50 50	50 49 49
NTEGUMENTARY SYSTEM			
*SKIN INFLAMMATION, NOS ULCER, NOS	(10)	(50) 1 (2%) 2 (4%)	(49) 1 (2 %)
ESPIRATORY SYSTEM			
<pre>#LUNG INFLAMMATICN, CHRONIC HYPERPLASIA, ADENOMATOUS</pre>	(10)	(49)	(48) 1 (2%) 1 (2%)
EMATOPOIETIC SYSTEM			
NONE			
IRCULATORY SYSTEM			
NONE			
IGESTIVE SYSTEM			
#STCMACH DIVERTICULUM	(10)	(49)	(48) 1 (2 %)
RINARY SYSTEM			
NONE			
NDOCRINE SYSTEM			
<pre>#THYROID FCLLICULAR CYST, NOS HYPERPLASIA, ADENOMATOUS HYPERPLASIA, FOLLICULAR-CELL</pre>	(10) 1 (10%)	(48)	(44) 1 (2%) <u>1 (2%)</u>

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
EPRODUCTIVE SYSTEM			
NONE			
IER VOUS SYSTEM			
NO N E			
PECIAL SENSE ORGANS			
NONE			
NUSCULOSKEIETAL SYSTEM			
NONE			
BODY CAVITIES			
NONB			
ALL OTHER SYSTEMS			
NONE	**		
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED AUTOLISIS/NO NECROPSI	5	29	30 1
NUMBER OF ANIMALS WITH TISSUE EX NUMBER OF ANIMALS NECROPSIED	AMINED MICROSCO	OP ICALLY	

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE FED PICLORAM IN THE DIET

TABLE D2.

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS FXAMINED HISTOPATHOLOGICALLY	10 10 10	50 49 49	50 50 50
INTEGUMENTARY SYSTEM NONE			
RESPIRATCRY SYSTEM			
#LUNG INFLAMMATICN, CHRONIC	(10) 1 (10%)	(49)	(50)
HEMATOPOIETIC SYSTEM			
#SPLEEN CCNGESTION, NOS HYPERPLASIA, LYMPHOID	(9)	(48) 1 (2 %)	(50) 1 (2%) 1 (2%)
CIRCULATORY SYSTEM			
NONE DIGESTIVE SYSTEM			
#LIVER INFLAMMATION, FOCAL INFLAMMATION, ACUTE FOCAL BASOPHILIC CYTO CHANGE	(10)	(49) 1 (2%) 1 (2%)	(50) 3 (6%)
#PANCREAS DILATATION/DUCTS INFLAMMATION, NOS	(9)	(49)	(50) 1 (2%) 1 (2%)
#COLCN ULCERNOS	(3)		(1) 1_(100 %

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
URINARY SYSTEM			. · · · ·
#KIDNEY INFLAMMATICN, CHRONIC	(10)	(49)	(50)
ENDOCRINE SYSTEM			
<pre>#THYROID FCLLICULAR CYST, NOS INFLAMMATION, FOCAL GRANULOMATOU</pre>	(10)	(47)	(45) 1 (2%) 1 (2%)
REPRODUCTIVE SYSTEM			
#UTERUS/ENDCMETRIUM HYPERPLASIA, CYSTIC	(10) 2 (20%)	(47)	(47)
#OVARY CYST, NOS	(10)	(47)	(49) 1 (2%)
FOLLICULAR CYST, NOS INFLAMMATION, NOS INFLAMMATION, SUPPURATIVE	2 (20%)	16 (34%)	9 (18%) 5 (10%)
NERVOUS SYSTEM			
#BRAIN Hydrccephalus, Nos Corpora amylacea	(10) 1 (10%)	(49)	(49) 1 (2%)
SPECIAL SENSE ORGANS			
NONE			
MUS CULOS KELETAL SYSTEM			
NONE			
BODY CAVITIES			
NONE			
ALL OTHER SYSTEMS			
NONE			
* NUMBER OF ANIMALS WITH TISSUE EXAM * NUMBER OF ANIMALS NECROPSIED	INED MICROSCOP	ICALLY	

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE			
SPECIAL MORPHOLOGY SUMMARY						
NO LESION REPORTED Autolysis/No NECROPSY	5	27 1	26			
# NUMBER OF AN IMALS WITH TISSUE EXA * NUMBER CF AN IMALS NECROPSIED	HINEE MICROSCO	PICALLY				

APPENDIX E

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS

IN RATS FED PICLORAM IN THE DIET

Topography: Morphology	Matched Control	Pooled Control	Low Dose	High Do <u>se</u>
Spleen: Hemangioma ^b	0/10 (0.00)	1/36 (0.03)	3/50 (0.06)	1/50 (0.02)
opreent nemangroma	0,10 (0.00)	1,30 (0.03)	5,50 (0.00)	1,50 (0002)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.134	0.012
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			2.160	0.720
Lower Limit			0.183	0.009
Upper Limit			111.051	55.415
Weeks to First Observed Tumor			113	106
Liver: Neoplastic Nodule ^b	0/10 (0.00)	0/38 (0.00)	3/49 (0.06)	0/49 (0.00)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Departure from Linear Trend ^e		P = 0.020		
Relative Risk (Matched Control) ^f			Infinite	
Lower Limit			0.137	
Upper Limit			Infinite	
Relative Risk (Pooled Control) ^f			Infinite	
Lower Limit			0.470	
Upper Limit			Infinite	
Weeks to First Observed Tumor			113	

		Fed Piclor	am in the Di et^a		
	(continued)				
		Matched	Pooled	Low	High
	Topography: Morphology	Control	<u>Control</u>	Dose	Dose
	Pituitary: Chromophobe Adenoma ^b	2/9 (0.22)	9/36 (0.25)	2/46 (0.04)	9/45 (0.20)
	P Values ^{c,d}	N.S.	N.S.	P = 0.008**(N)	N.S.
	Departure from Linear Trend ^e	P = 0.033	P = 0.007		
	Relative Risk (Matched Control) ^f			0.196	0.900
	Lower Limit			0.018	0.250
	Upper Limit			2.519	7.901
76	Relative Risk (Pooled Control) ^f			0.174	0.800
	Lower Limit			0.019	0.318
	Upper Limit			0.776	2.042
	Weeks to First Observed Tumor	113		113	83

Table El.	Analyses of	the Incidenc	e of Prim ary	Tumors	in Male Rats
	Fe	ed Picloram in	n the Di et^a		

	Matched	Pooled	Low	High
Topography: Morphology	<u>Control</u>	<u>Control</u>	Dose	Dose
Thyroid: C-cell Adenoma ^b	0/9 (0.00)	1/36 (0.03)	6/47 (0.13)	1/49 (0.02)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Departure from Linear Trend ^e	P = 0.042	P = 0.018		
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.347	0.011
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			4.596	0.735
Lower Limit			0.595	0.010
Upper Limit			206.379	56.525
Weeks to First Observed Tumor			113	113

	Matched	Pooled	Low	High
Topography: Morphology	Control	<u>Control</u>	Dose	Dose
Adrenal: Cortical Adenoma ^b	0/10 (0.00)	0/36 (0.00)	2/49 (0.04)	0/49 (0.00)
P Values ^c ,d	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	
Lower Limit			0.067	
Upper Limit			Infinite	
Relative Risk (Pooled Control) ^f			Infinite	
Lower Limit			0.220	
Upper Limit			Infinite	
Weeks to First Observed Tumor			83	

^aTreated groups received time-weighted average doses of 7,437 or 14,875 ppm.

81

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05 otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooled-control group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d A negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specified control group.

Topography: Morphology	Matched Control	Pooled Control	Low <u>Dose</u>	High <u>Dose</u>
Liver: Neoplastic Nodule ^b	0/10 (0.00)	0/39 (0.00)	5/50 (0.10)	7/49 (0.14)
P Values ^{c,d}	N.S.	P = 0.016	N.S.	P = 0.014**
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.281	0.441
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			Infinite	Infinite
Lower Limit			0.989	1.557
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			99	88
Pituitary: Chromophobe				
Pituitary: Chromophobe Adenoma ^b	0/9 (0.00)	4/37 (0.11)	7/48 (0.15)	7/46 (0.15)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.413	0.430
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			1.349	1.408
Lower Limit			0.375	0.392
Upper Limit			5.873	6.116
Weeks to First Observed Tumor			109	94

(continued)				
	Matched	Pooled	Low	High
Topography: Morphology	Control	<u>Control</u>	Dose	Dose
Thyroid: C-cell Adenoma ^b	0/9 (0.00)	1/38 (0.03)	3/46 (0.07)	7/46 (0.15)
P Values ^{c,d}	N.S.	P = 0.029	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.132	0.430
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			2.478	5,783
Lower Limit			0.209	0.796
Upper Limit			127.174	254.145
Weeks to First Observed Tumor			113	114
Adrenal: Cortical Adenoma ^b	0/8 (0.00)	0/37 (0.00)	2/50 (0.04)	4/48 (0.08)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.054	0.179
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			Infinite	Infinite
Lower Limit			0.222	0.719
Upper Limit			Infinite	Infinite
Weeks to First Observed Tumor			81	104

(continued)				
	Matched	Pooled	Low	High
Topography: Morphology	<u>Control</u>	<u>Control</u>	Dose	Dose
Mammary Gland:				
Fibroadenoma ^b	0/10 (0.00)	7/39 (0.18)	6/50 (0.12)	4/50 (0.08)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			Infinite	Infinite
Lower Limit			0.356	0.206
Upper Limit			Infinite	Infinite
Relative Risk (Pooled Control) ^f			0.669	0.446
Lower Limit			0.203	0.103
Upper Limit			2.142	1.626
Weeks to First Observed Tumor	5 22 4 30		63	63
Uterus: Endometrial				
Stromal Polyp ^b	1/10 (0.10)	3/39 (0.08)	8/48 (0.17)	4/45 (0.09)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			1.667	0.889
Lower Limit			0.278	0.108
Upper Limit			72.240	42.792
Relative Risk (Pooled Control) ^f			2.167	1.156
Lower Limit			0,565	0.208
Upper Limit			11.972	7.468
Weeks to First Observed Tumor	113		81	104

(continued)

^aTreated groups received time-weighted average doses of 7,437 or 14,875 ppm.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^cBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooled-control group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d A negative trend (N) indicates a lower incidence in a treated group than in a control group.

82

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specified control group.

APPENDIX F

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS

IN MICE FED PICLORAM IN THE DIET

	Matched	Pooled	Low	High
Topography: Morphology	<u>Control</u>	<u>Control</u>	Dose	Dose
Lung: Alveolar/Bronchiolar				
Adenoma or Carcinoma ^b	1/10 (0.10)	2/38 (0.05)	5/49 (0.10)	3/48 (0.06)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			1.020	0.625
Lower Limit			0.141	0.061
Upper Limit			47.261	32.146
Relative Risk (Pooled Control) ^f			1.939	1.188
Lower Limit			0.339	0.143
Upper Limit			19.554	13.675
Weeks to First Observed Tumor	90		76	91
Liver: Hepatoce llular Carcinoma ^b	4/10 (0.40)	8/38 (0.21)	11/49 (0.22)	4/49 (0.08)
P Values ^{c,d}	P = 0.007 (N)	N.S.	N.S.	P = 0.022* (N
Relative Risk (Matched Control) ^f			0.561	0.204
Lower Limit			0.235	0.053
Upper Limit			2.094	0.963
Relative Risk (Pooled Control) ^f			1.066	0.388
Lower Limit	·		0.437	0.093
Upper Limit			2.765	1.337
Weeks to First Observed Tumor	62		87	81

85

(continued)				
	Matched	Pooled	Low	High
Topography: Morphology	Control	Control	Dose	Dose
Liver: Hepatocellular Carcinoma				
or Adenoma or Neoplastic Nodule ^b	5/10 (0.50)	9/38 (0.24)	13/49 (0.27)	8/49 (0.16)
P Values ^{c,d}	P = 0.020 (N)	N.S.	N.S.	P = 0.033* (N)
Relative Risk (Matched Control) ^f			0.531	0.327
Lower Limit			0.264	0.140
Upper Limit			1.595	1.077
Relative Risk (Pooled Control) ^f			1.120	0.689
Lower Limit			0.501	0.257
Upper Limit			2.663	1.827
Weeks to First Observed Tumor	62		87	81

98

^aTreated groups received time-weighted average doses of 2,531 or 5,062 ppm.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooled-control group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d_A negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specified control group.

	Matched	Pooled	Low	High
Topography: Morphology	<u>Control</u>	Control	Dose	Dose
Lung: Alveolar/Bronchiolar				
Adenoma ^b	1/10 (0.10)	2/39 (0.05)	1/49 (0.02)	0/50 (0.00)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f			0.204	0.000
Lower Limit			0.003	0.000
Upper Limit			15.723	3.747
Relative Risk (Pooled Control) ^f			0.398	0.000
Lower Limit			0.007	0.000
Upper Limit			7.377	2.634
Weeks to First Observed Tumor	90		90	
Liver: Hepatocellular				
Carcinoma ^b	0/10 (0.00)	3/39 (0.00)	0/49 (0.00)	1/50 (0.02)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Matched Control) ^f				Infinite
Lower Limit				0.012
Upper Limit				Infinite
Relative Risk (Pooled Control) ^f			0.000	0.260
Lower Limit			0.000	0.005
Upper Limit			1.321	3.097
Weeks to First Observed Tumor				91

(continued)

^aTreated groups received time-weighted average dose of 2,531 or 5,062 ppm.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when P < 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched-control group (*) or with the pooled-control group (**) when P < 0.05 for either control group; otherwise, not significant (N.S.) is indicated.

 d A negative trend (N) indicates a lower incidence in a treated group than in a control group.

88

^eThe probability level for departure from linear trend is given when P < 0.05 for any comparison.

 $^{\rm f}$ The 95% confidence interval of the relative risk between each treated group and the specified control group.

APPENDIX G

ANALYSIS OF FORMULATED DIETS FOR

CONCENTRATIONS OF PICLORAM

APPENDIX G

Analysis of Formulated Diets for Concentrations of Picloram

A 10-g sample of the dosage mixture to be analyzed was shaken with 125 ml methanol for 16 hours. The mixture was then filtered through Celite with methanol washes, and the combined methanol solution was reduced to 10 ml. After appropriate dilutions, the solution was quantitatively analyzed for picloram by gas-liquid chromatography (electron capture detector, 10% DC-200 on Gas Chrom Q column). External standards were used for calibrations, and recoveries were determined with spiked samples.

Theoretical Concentrations in Diet (ppm)	No. of Samples	Sample Analytical Mean (ppm)	Coefficient of Variation (%)	Range (ppm)
2,500	19	2,494	3.1%	2,340-2,670
5,000	19	4,984	4.0%	4,660-5,400
10,000	23	9,922	6.7%	9,200-11,200
20,000	10	19,560	3.5%	18,700-20,600

* U. S. GOVERNMENT PRINTING OFFICE : 1978 260-899/3186

DHEW Publication No. (NIH) 78-823